PolyRemedy, Inc. manufactures robotic systems for the fabrication of nano-material based wound dressings at the point-of-care, allowing wound care clinicians to deliver easily and cost-effectively customized wound care on-demand for each patient's unique wound.
Proxeon develops state-of-the-art solutions to solve many of the scientific and technical challenges that are faced by those working in the field of proteomics. The company's core competencies are in the areas of mass spectrometry, protein analysis, hardware and software design for proteome analysis.
A provider of innovative technologies and products for preanalytical sample preparation and molecular diagnostics solutions such as the HiLight Array System that uses Resonance Light Scattering (RLS), a technology based on the optical light scattering properties of nano-sized metal colloid particles.
Quanterix Corporation is developing a novel platform for single molecule analysis that will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research.
Randox Food Diagnostics is a division of Randox Laboratories who have 30 years experience in the diagnostic market and a devoted research and development team. Randox Food Diagnostics is a dedicated company responsible for the distribution of Randox drug residue kits, wine testing kits and analysers worldwide. Randox Food Diagnostics incorporate several market related products dedicated to the food, wine and beverage industries. Randox uses in house developed antibodies and conjugates for a wide range of their screening products including the patented Biochip Array Technology (multiplex screening platform).
A highly specialized research and development company that focuses on developing medical diagnostic devices. The range of skills within RD Support enables efficient Design for Manufacture (DFM) product development.
Rexahn and the University of Maryland, Baltimore (UMB) Center for Nanomedicine & Cellular Delivery (CNCD), are jointly pursuing the development of water-soluble nano-polymers for targeted delivery of anticancer drugs.
RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of serious human diseases. The company has developed novel and proprietary nanotransporters that have been shown to deliver RNAi compounds to target tissues in animal models.
Senova Systems owns an exclusive worldwide license from Oxford University for a breakthrough pH sensor that does not require calibration, is not subject to fouling, and does not drift with changes in temperature. The company is developing these revolutionary new pH Meters to meet specific needs in all process industries.
Develops, manufactures, and sells a broad range of biological based materials and services essential for the manufacture of diagnostic tests, commercial bioproduction of therapeutic drugs,including clinically annotated DNA and RNA.
Silicon Biosystems has developed a set of proprietary solutions called lab-on-a-chip technologies, targeted at miniaturized cell-biology testing. Silicon Biosystems exploits the microelectronics potential in order to produce miniaturized cellular biology laboratories.
Sirnaomics, Inc. is dedicated to becoming the leader in the RNAi technology focusing on (1) enhancement of the potency of active pharmaceutical ingredient (API) using multi-targeted small interfering RNA (siRNA) cocktail; (2) improvement of the API delivery in vivo using clinical viable synthetic polymeric and lipid nanoparticles.